60925-61-3

Ceforanide is a second generation cephalosporin with good β-lactamase resistance. It has a serum half-life of about three hours, allowing twice-daily dosing.

Bristol (USA)

Cephalosporin antibiotic

ChEBI: A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many col forms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Ari ona species.

Precef (Apothecon).

A semisynthetic parenteral cephalosporin with activity broadly similar to that of cefalotin. Its activity in vitro is significantly reduced in the presence of serum. A 1 g intravenous dose achieves a concentration of c. 135 mg/L at the end of infusion. The response after 0.25, 0.5 and 1 g intravenous doses is essentially linear. A 1 g intramuscular dose produces mean peak values of around 70 mg/L. Plasma protein binding is around 85%.
It is almost entirely eliminated in the urine with a halflife of about 2.5 h, 80–95% being recovered in the first 12 h. The half-life is inversely related to renal function, rising to around 20 h when the creatinine clearance falls below 5 mL/min. About half the dose is removed by hemodialysis over 6 h.
It is generally well tolerated; phlebitis and pain at the site of injection are reported in some patients with occasional transient neutropenia and increased transaminase levels. It has been used principally for the treatment of infections due to Gram-positive cocci, including staphylococcal and streptococcal soft-tissue infections, but is no longer widely available.

-20°C, away from moisture